Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.
2.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698.

PMID:
21506632
3.

The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.

Gionis MN, Ioannou CV, Katsamouris AN, Katonis P, Balalis K, Sfyridaki K, Elalamy I, Gerotziafas GT.

Thromb Res. 2013;132(6):685-91. doi: 10.1016/j.thromres.2013.09.037.

PMID:
24182549
4.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
5.

Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.

Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187.

PMID:
21748826
6.

Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.

Postma MJ, Kappelhoff BS, van Hulst M, Brouwers JR.

J Med Econ. 2012;15(5):878-86. doi: 10.3111/13696998.2012.691144.

PMID:
22563715
7.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

9.

Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement.

Lalmohamed A, Vestergaard P, Jansen PA, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F.

J Thromb Haemost. 2013 Apr;11(4):642-50. doi: 10.1111/jth.12158.

10.

Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.

Selby R, Borah BJ, McDonald HP, Henk HJ, Crowther M, Wells PS.

Thromb Res. 2012 Aug;130(2):166-72. doi: 10.1016/j.thromres.2012.01.013.

PMID:
22365491
11.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
12.

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203.

PMID:
22023098
13.

Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.

Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S; PROPICE Study Group..

Thromb Haemost. 2012 Jun;107(6):1151-60. doi: 10.1160/TH11-09-0640.

PMID:
22476471
14.
15.

The prevalence of venous thromboembolism after hip and knee replacement surgery.

O'Reilly RF, Burgess IA, Zicat B.

Med J Aust. 2005 Feb 21;182(4):154-9.

PMID:
15720169
16.

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.

McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.

J Med Econ. 2012;15(5):817-28. doi: 10.3111/13696998.2012.684116.

PMID:
22494267
17.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.

Thromb Haemost. 2010 Oct;104(4):760-70. doi: 10.1160/TH10-01-0071. Review.

PMID:
20806107
18.
19.

Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care.

Navarro RP, Barr JE, Faubus K, Sabharwal AD, Stern E, Unger K.

Am J Manag Care. 2011 Jul;17 Suppl 9:S251-8. Review.

PMID:
21819165
20.

Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.

Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR.

CMAJ. 2008 Jun 3;178(12):1545-54. doi: 10.1503/cmaj.071388. Erratum in: CMAJ. 2008 Jul 1;179(1):56.

Items per page

Supplemental Content

Support Center